Summary of Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2021

Summary of Significant Accounting Policies

Schedule of reconciliation of the cash, cash equivalents and restricted cash amounts

	March 31, 2021		March 31, 2020
Cash and cash equivalents	$	81,290	$	101,455
Restricted cash, included in other assets		5,000		—
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	86,290	$	101,455

Schedule of the Company's net sales by medical indication

	Three Months Ended				Nine Months Ended
(In thousands)	March 31,				March 31,
Medical Indication	2021		2020		2021		2020
Analgesic	$	3,836	$	2,811	$	10,528	$	6,806
Anti-Psychosis		11,678		27,858		38,023		78,588
Cardiovascular		16,573		21,746		52,623		67,325
Central Nervous System		24,509		18,566		71,648		57,154
Endocrinology		6,822		—		19,551		—
Gastrointestinal		16,817		20,745		52,492		56,020
Infectious Disease		10,610		21,749		55,586		51,722
Migraine		5,169		12,886		20,942		32,907
Respiratory/Allergy/Cough/Cold		2,548		2,966		6,241		8,747
Urinary		1,566		1,149		4,385		2,817
Other		8,617		8,051		24,661		27,847
Contract manufacturing revenue		3,625		5,845		16,089		17,891
Total net sales	$	112,370	$	144,372	$	372,769	$	407,824

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2021		2020		2021		2020
Product 1	8	%	11	%	13	%	10	%
Product 2	8	%	17	%	8	%	18	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2021		2020		2021		2020
Customer A	29	%	29	%	27	%	25	%
Customer B	20	%	21	%	21	%	24	%
Customer C	13	%	12	%	12	%	11	%